Clinical Trial Update: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial compares the efficacy and safety of adding a new treatment to tislelizumab in non-small cell lung cancer. The study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING